EyePoint announced a strategic reduction of its workforce by over half and a pause of wet AMD trials following a failed Phase 3 study for DURAVYU, shifting focus to its DME program to conserve $30 million in annual cash.
EyePoint announced a strategic reduction of its workforce by over half and a pause of wet AMD trials following a failed Phase 3 study for DURAVYU, shifting focus to its DME program to conserve $30 million in annual cash.